 |
市場調查報告書
商品編碼
1773138
NPS+（美國）- 腎細胞癌NPS+ (US) - Renal Cell Carcinoma |
||||||
本報告基於100位美國腫瘤學家的洞見，分析了美國腎細胞癌治療領域的競爭格局。運用NPS+框架，透過比較不同主要治療方案的淨推薦值，並分析醫師滿意度和忠誠度背後的驅動因素，提供品牌健康狀況的詳細視圖。本報告探討了推薦者和批評者對品牌認知的差異、與主要品牌最相關的資訊以及忠誠醫生的處方價值。還透過識別轉換風險並揭示每個品牌相對於競爭對手的定位，清晰地洞察當前的市場動態以及未來對品牌佔有率的威脅。
關鍵問題
- 1.不同品牌的NPS分數如何比較？
- 2.醫師對特定品牌的忠誠度如何？
- 3.哪些品牌訊息能引起醫師的共鳴？
- 4.影響醫師選擇的主要因素有哪些？
- 5.主要品牌的市場佔有率是多少？
- 6.主要品牌與競爭對手相比如何？
- 7.哪些品牌可能會因品牌滿意度低而轉換？
主要品牌
|
|
方法論：
First View 報告是基於透過 LiMATM 篩選出的醫生進行的定量調查得出。 LiMATM 是全球最大的醫生名錄，擁有超過 300萬名經過驗證的醫生。每位醫生都經過嚴格的篩選標準，以確保收集到的見解具有相關性、可靠性，並反映頂尖醫療專業人士的真實感受和經驗。調查結果以易於理解的圖表形式呈現，方便快速理解和分析資料。憑藉 LiMATM 的廣泛覆蓋範圍和精準度，FirstView Reports 提供無與倫比的資料驅動洞察，指導策略規劃，並在快速發展的醫療保健領域保持領先地位。
報告有何特別之處？
FirstWord Reports 是值得信賴的行業領導者，致力於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的洞察。深厚的行業知識使能夠提供相關且有價值的洞察，幫助掌握新興趨勢，有效應對複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，報告可提供所需的準確性和可靠性。獨家獲取其他地方無法獲得的採訪和資料，以及持續的市場監測，確保全面了解市場動態。報告涵蓋 40 多個動態疾病領域、包括 KOL 洞察和定量醫生調查在內的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使能夠做出更明智的、資料驅動的決策，在快速變化的行業中保持競爭力。
This report examines the competitive landscape of US Renal Cell Carcinoma therapies, drawing on insights from 100 US oncologists. Using the NPS+ framework, it provides a detailed view of brand health by comparing Net Promoter Scores across key therapies and analyzing the underlying drivers of physician satisfaction and loyalty. The report explores how brand perceptions differ between Promoters and Detractors, the messages most associated with leading brands, and the prescribing value of loyal physicians. It also identifies switching risks and reveals how each brand is positioned relative to its competitors, offering a clear view of current market dynamics and future threats to brand share.
Key Questions Answered:
- 1. How do NPS scores by brand compare?
- 2. How loyal are physicians to specific brands?
- 3. What brand messages resonate with physicians?
- 4. What are the key factors driving physician choice?
- 5. What is the market share of leading brands?
- 6. How does each of the leading brands compare to its competitors?
- 7. Which brands are vulnerable to switching due to low brand satisfaction?
Key Brands:
|
|
Methodology:
FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
